title: Bioequivalence study of 8 mg ondansetron film-coated tablets in healthy Caucasian volunteers.
abstract: The aim of the study was to investigate the bioequivalence of a generic product of 8 mg film-coated tablets (test) to the branded product (reference) at the same strength in order to apply for regulatory approval. The secondary objective of the study was to compare the tolerability of both products. A double blinded, randomized, cross-over, 2-period, comparative study was conducted in healthy Caucasian volunteers under fasting conditions. A single oral dose administration of the test or reference product was followed by a 7-day wash-out period. The ondansetron concentration was determined using a validated high performance liquid chromatography with a UV detection method. The 90% confidence interval of the point estimate (test over reference products) for C(max) and AUC(0-t) fell within the 80.00-125.00% acceptance range. The results of the study indicate that the film-coated tablets of Ondatron 8 mg manufactured by Tarchomińskie Zakłady Farmaceutyczne Polfa S.A. (test product) are bioequivalent to those of Zofran manufactured by GlaxoSmithKline Export Ltd (reference product). Both products were well tolerated.
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: P J
authors.initials: PJ
authors.lastname: Rudzki
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Kaza
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Leś
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: E
authors.initials: E
authors.lastname: Gilant
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: H
authors.initials: H
authors.lastname: Ksycińska
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: K
authors.initials: K
authors.lastname: Serafin-Byczak
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Troć
authors.affiliation: Clinical Centre CRO Poland Sp. z o. o., Otwock, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Raszek
authors.affiliation: Tarchomińskie Zakłady Farmaceutyczne Polfa S.A., Warsaw, Poland.
authors.forename: E
authors.initials: E
authors.lastname: Piątkowska-Chabuda
authors.affiliation: Tarchomińskie Zakłady Farmaceutyczne Polfa S.A., Warsaw, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Skowrońska-Smolak
authors.affiliation: Tarchomińskie Zakłady Farmaceutyczne Polfa S.A., Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Tarasiuk
authors.affiliation: Pharmacology Department, Pharmaceutical Research Institute, Warsaw, Poland.
authors.forename: E
authors.initials: E
authors.lastname: Wilkowska
authors.affiliation: Clinical Centre CRO Poland Sp. z o. o., Otwock, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Łazowski
mesh_terms: D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D017294:Ondansetron / Q000009:adverse effects / Q000493:pharmacokinetics*; D013607:Tablets; D013810:Therapeutic Equivalency
chemical_list: D013607:Tablets; D017294:Ondansetron